文献速递乳腺癌

早期乳腺癌中的蒽环类药物:ABC试验—USOR 06-090、NSABP B-46-I/USOR 07132和NSABP B-49(NRG肿瘤学)

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
PubMed 文献 · J Clin Oncol · 2017-04-11

中位随访3.3年时,TC6对比TaxAC的iDFS风险比HR为1.202(95%CI 0.97-1.49),触发无效性早期报告;4年iDFS TC6组88.2% vs TaxAC组90.7%(P=0.04)。结论认为TaxAC方案较TC6改善iDFS。

要点

  • TC6对比TaxAC的iDFS风险比HR为1.202(95%CI 0.97-1.49),超过预设无效界值1.18,触发早期无效性报告。
  • 4年iDFS:TC6组88.2% vs TaxAC组90.7%(P=0.04)。
  • 按方案、激素受体状态和淋巴结状态的治疗交互检验均为阴性。

核心结论

  • 在高危人表皮生长因子受体2阴性乳腺癌患者中,TaxAC方案较TC6方案改善无侵袭性疾病生存(iDFS)。

研究设计与样本

  • 系列三项辅助试验:USOR 06-090比较TC6与TAC6;NSABP B-46-I/USOR 07132比较TC6、TAC6或TC6联合贝伐珠单抗;NSABP B-49比较TC6与多种标准AC联合紫杉类方案。
  • 在分析各单项试验前,预先计划对TC对比TaxAC方案进行联合疗效分析,主要终点为无侵袭性疾病生存(iDFS)。
  • 共2125例患者随机接受TC6方案,2117例患者随机接受TaxAC方案。
  • 接受TC6联合贝伐珠单抗的患者未纳入分析。
  • 预设无效性界值为:分层Cox模型得出的TC6对比TaxAC风险比(HR)超过1.18即判定TC6劣效。

主要发现

  • 中位随访时间为3.3年。
  • 共观察到334例iDFS事件,TC6对比TaxAC的HR为1.202(95%CI 0.97-1.49),触发无效性早期报告。
  • 4年iDFS:TC6组为88.2%,TaxAC组为90.7%(P=0.04)。
  • 按方案、激素受体状态和淋巴结状态的治疗交互检验均为阴性。

关键数值与推荐

  • 预设无效性界值:TC6对比TaxAC的HR超过1.18判定TC6劣效。
  • 中期监测触发报告无效性的条件:观察到334例iDFS事件时HR大于1.18。
  • TC6对比TaxAC的HR为1.202(95%CI 0.97-1.49)。
  • 4年iDFS:TC6组88.2% vs TaxAC组90.7%(P=0.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to AC regimens with a taxane (TaxAC) is unknown. Methods In a series of three adjuvant trials, women were randomly assigned to TC for six cycles (TC6) or to a standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TAC6, or TC6 plus bevacizumab. NSABP B-49 compared TC6 with several standard AC and taxane combination regimens. Before any analysis of individual trials, a joint efficacy analysis of TC versus the TaxAC regimens was planned, with invasive disease-free survival (IDFS) as the primary end point. Patients who received TC6 plus bevacizumab on NSABP B-46-I/USOR 07132 were not included. A hazard ratio (HR) from a stratified Cox model that exceeded 1.18 for TC6 versus TaxAC was predefined as inferiority for TC6. The prespecified interim monitoring plan was to report for futility if the HR was > 1.18 when 334 IDFS events were observed (50% of 668 events required for definitive analysis). Results A total of 2,125 patients were randomly assigned to receive TC6 regimens and 2,117 patients were randomly assigned to receive TaxAC regimens. The median follow-up time was 3.3 years. There were 334 IDFS events, and the HR for TC6 versus TaxAC was 1.202 (95% CI, 0.97 to 1.49), which triggered early reporting for futility. The 4-year IDFS was 88.2% for TC6 and was 90.7% for TaxAC ( P = .04). Tests for treatment interaction by protocol, hormone receptor status, and nodal status were negative. Conclusion The TaxAC regimens improved IDFS in patients with high-risk human epidermal growth factor receptor 2-negative breast cancer compared with the TC6 regimen.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017. PMID: 28398846. doi:10.1200/JCO.2016.71.4147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。